AFG3L2

Across TCGA pan-cancer cohorts, AFG3L2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of AFG3L2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where AFG3L2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types AFG3L2 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, LSCC, and LUAD are the cancer types where AFG3L2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AFG3L2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	−0.800	<.001	10	view →
LSCC	Male	III,IV	+0.744	<.001	8	view →
LUAD	Male	II,III,IV	+0.470	<.001	8	view →
PDAC	Male	All	−0.724	<.001	6	view →
COAD	Female	II,III,IV	−0.126	.015	5	view →
HNSC	Female	IV	−0.360	.015	3	view →
OV	All	All	+0.539	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

AFG3L2–CCRCC

Open the CCRCC breakdown →